Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rite Aid settles Germ Defense case

This article was originally published in The Tan Sheet

Executive Summary

Rite Aid Corp. agrees to pay $50,000 to settle Federal Trade Commission allegations it misled consumers by advertising the Germ Defense supplement could treat and prevent colds and flu. Rite Aid compared Germ Defense, manufactured for the chain by Improvita Health Products, to Airborne Health Inc.'s Airborne, according to FTC's complaint filed in U.S. District Court for the Middle District of Pennsylvania. Airborne Health faced similar FTC charges and agreed to pay up to $30 million in consumer redress for misleading advertising (1"The Tan Sheet" Aug. 18, 2008). FTC is currently litigating a related complaint against Cleveland-based Improvita in U.S. District Court for the Northern District of Ohio

You may also be interested in...



FTC cuts checks in Rite Aid settlement

The Federal Trade Commission distributed more than 2,335 refund checks to consumers who purchased Rite Aid Germ Defense tablets and lozenges, stemming from the agency's July 2009 complaint against Rite Aid for unsupported claims that the products could reduce the risk of, or prevent colds and flu (1"The Tan Sheet" July 20, 2009). As part of a settlement with the firm, FTC mailed refund checks to consumers on June 7; consumers could submit refund requests for up to six packages of Germ Defense, either electronically or by mail, by Jan. 30. The average check totals $20.44, FTC says. The agency charged Rite Aid and its supplier with false and deceptive advertising as part of its crackdown on firms making "unproven" claims about cold and flu remedies

CVS settles AirShield case

CVS Pharmacy will pay nearly $2.8 million to settle FTC allegations it falsely advertised that its AirShield dietary supplement prevents colds, fights germs and boosts the immune system. FTC alleged the drugstore chain had no evidence to support the claims, according to a Sept. 8 FTC announcement. The allegations are similar to those FTC made against Airborne Health, Improvita Health Products and Rite Aid for similar supplements. Rite Aid paid $500,000 to settle allegations its Germ Defense ads misled consumers (1"The Tan Sheet" July 20, 2009). Airborne agreed to pay up to $30 million in consumer redress for alleged false ads (2"The Tan Sheet" Aug. 18, 2008). FTC is in litigation with Improvita

FTC Settlement Looks To Ground Airborne Claims

Under a settlement with the Federal Trade Commission announced Aug. 14, the maker of Airborne dietary supplement products must cease unsubstantiated health-related claims and contribute up to $6.5 million to an existing consumer redress fund

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel